MacroGenics. has filed a patent for methods of treating cancer and other diseases using modified polypeptides, particularly antibodies, with variant Fc regions. These molecules bind to specific receptors to enhance or inhibit cellular responses, offering potential treatments for various conditions like cancer, infections, inflammation, and autoimmune diseases. GlobalData’s report on MacroGenics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights MacroGenics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on MacroGenics, Personalized cancer vaccines was a key innovation area identified from patents. MacroGenics's grant share as of January 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

Therapeutic method using modified polypeptides for treating diseases

Source: United States Patent and Trademark Office (USPTO). Credit: MacroGenics Inc

A patent application (Publication Number: US20240018261A1) discloses a method for treating diseases by administering a polypeptide with a variant Fc region that binds to target cells and ameliorates disease symptoms. The variant Fc region has altered affinities to Fc?RActivating and Fc?Inhibiting compared to wild-type immunoglobulins. The method involves using a portion of an antibody, such as a monoclonal, chimeric, humanized, or human antibody, with specific variable domains that bind to various cell surface markers. The variant Fc region may have amino acid modifications at specific positions, affecting its binding properties and effector functions.

Furthermore, the patent application describes different scenarios where the variant Fc region's Ratio of Affinities can either inhibit or activate effector functions of target cells, depending on the amino acid substitutions present. The method can be applied to treat inflammatory disorders, autoimmune diseases, infectious diseases, and cancer by targeting specific antigens associated with these conditions. Additionally, the treatment may involve combining the polypeptide with other cancer therapies like chemotherapy, immunotherapy, radiation therapy, hormonal therapy, or surgery. Overall, the method outlined in the patent application aims to provide a personalized and effective approach to treating various diseases in human subjects using the unique properties of the variant Fc region.

To know more about GlobalData’s detailed insights on MacroGenics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies